4:02 PM
 | 
Jun 27, 2017
 |  BC Innovations  |  Distillery Techniques

Drug platforms; drug delivery

TECHNOLOGY: Nucleic acids; other

A method for delivering bispecific T cell-engaging antibodies as engineered mRNAs could prolong the serum half-life of the antibodies to treat cancer. mRNA encoding bispecific antibodies targeting CD3 and a second tumor antigen were engineered as single-stranded molecules with modified 3’ and 5’ untranslated regions (UTRs) and polyadenine (polyA) tails to enhance stability and...

Read the full 270 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >